CIR Expert Panel To Prioritize Cannabidiol Review In 2024 At FDA’s Request
Cosmetic Ingredient Review’s independent experts note that CBD use in cosmetic products has increased since FDA first asked them to prioritize its review in 2020.
You may also be interested in...
The US-based Expert Panel for Cosmetic Ingredient Safety issued three final and six tentative safety assessments and three insufficient data announcements at its 12-13 June meeting in Washington.
Cosmetic Ingredient Review’s independent expert panel finalized assessments of seven ingredients at the 6-7 March meeting, advanced two tentative safety assessments, and issued three insufficient data announcements. Propolis extract was added to the group’s 2023 priorities list while 2024 priorities remain open to public comment.
Industry trade groups say FDA decision against starting rulemaking for lawful use of hemp ingredients is not only overdue but failed to clear the air for businesses making or using the ingredients.